Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions

Abstract

The present invention relates to a method for treating skin diseases and skin conditions in a patient in need thereof which comprises of administering a therapeutically effective amount of a pharmaceutical composition comprising a therapeutically effective amount of 7-(1H-Imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline, or its individual enantiomers or the tautomers thereof, or a pharmaceutically acceptable salt thereof.

What is claimed is: 
     
         1 . A method for treating skin conditions in a patient suffering thereof, which comprises treating said patient with a pharmaceutical composition comprising a therapeutically effective amount of 7-(1H-Imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline, or the individual enantiomers thereof, or the individual tautomers thereof, or a pharmaceutically acceptable salt thereof. 
     
     
         2 . The method according to  claim 1 , wherein the pharmaceutical composition comprises (R)-(−)-7-(1H-Imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline. 
     
     
         3 . The method according to  claim 1 , wherein the pharmaceutical composition comprises (S)-(+)-7-(1H-Imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline. 
     
     
         4 . The method according to  claim 1 , wherein the treated condition is selected from: rosacea, rosacea fulminans, sunburn, psoriasis, menopause-associated hot flashes, flushing and redness associated with hot flashes, erythema associated with hot flashes, hot flashes resulting from orchiectomyatopic dermatitis, treatment of redness and itch from insect bites, photoaging, seborrheic dermatitis, acne, allergic dermatitis, telangiectasia (dilations of previously existing small blood vessels) of the face, angioectasias, rhinophyma (hypertrophy of the nose with follicular dilation), acne-like skin eruptions (may ooze or crust), burning or stinging sensation, erythema of the skin, cutaneous hyperactivity with dilation of blood vessels of the skin, Lyell's syndrome, Stevens-Johnson syndrome, local itching and discomfort associated with hemorrhoids, hemorrhoids, erythema multiforme minor, erythema multiforme major, erythema nodosum, eye puffiness, urticaria, pruritis, purpura, varicose veins, contact dermatitis, atopic dermatitis, nummular dermatitis, generalized exfoliative dermatitis, stasis dermatitis, lichen simplex chronicus, perioral dermatitis, pseudofolliculitis barbae, granuloma annulare, actinic keratosis, basal cell carcinoma, squamous cell carcinoma, and eczema. 
     
     
         5 . The method according to  claim 1 , wherein the condition is rosacea. 
     
     
         6 . The method according to  claim 1 , wherein the condition is psoriasis. 
     
     
         7 . The method according to  claim 1 , wherein the condition is rosacea fulminans. 
     
     
         8 . The method according to  claim 1 , wherein the condition is telangiectasia of the face. 
     
     
         9 . The method according to  claim 1 , wherein the condition is erythema of the skin. 
     
     
         10 . The method of  claim 1 , wherein said pharmaceutical composition is in a formulation suitable for topical dermatological administration, suspensions, gels, solutions, creams, lotions, ointments, foams, emulsions, microemulsions, milks, serums, aerosols, sprays, dispersions, microcapsules, vesicles, microparticles, wet cloths, dry cloths, facial cloths or direct injection. 
     
     
         11 . An article of manufacture comprising packaging material and a pharmaceutical agent contained within said packaging material, wherein the pharmaceutical agent is therapeutically effective for treating a skin condition and wherein the packaging material comprises a label which indicates the pharmaceutical agent can be used for treating a skin condition and wherein said pharmaceutical agent comprises a therapeutically effective amount of 7-(1H-Imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline or an enantiomer thereof. 
     
     
         12 . The article of manufacture according to  claim 11 , wherein said pharmaceutical agent comprises a therapeutically effective amount of (S)-(+)-7-(1H-Imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline. 
     
     
         13 . A method for treating ocular rosacea, pterygium or conjunctival hyperemia in a patient suffering thereof, which comprises treating said patient with a pharmaceutical composition comprising a therapeutically effective amount of 7-(1H-Imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline, or the individual enantiomers thereof, or the individual tautomers thereof, or a pharmaceutically acceptable salt thereof. 
     
     
         14 . The method according to  claim 13 , wherein the pharmaceutical composition comprises (R)-(−)-7-(1H-Imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline. 
     
     
         15 . The method according to  claim 13 , wherein the pharmaceutical composition comprises (S)-(+)-7-(1H-Imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline.